News | March 30, 2022
TDB approves funding for MIM in MedTech
Technology Development Board supports commercialisation of Metal Injection Molding of implants
Technology Development Board supports commercialisation of Metal Injection Molding of implants
Dupixent peak sales ambition raised to more than €13 billion
AbbVie to present 30 abstracts demonstrating its leadership in neuroscience, including continued migraine treatment research across the spectrum of the disease, commitment to patients with advanced Parkinson's disease, and new studies in spasticity and cervical dystonia
New collaboration will help customers reach sustainability goals for high-performance Udel PSU polymers in demanding applications.
Ozempic is now approved in the US at 0.5 mg,1.0 mg and 2.0 mg doses for the treatment of type 2 diabetes in adults
Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients
The companies are now preparing to initiate a Phase 1 trial to assess the safety and immunogenicity of BLB-201 in healthy volunteers
As a partner with IRIA, the company had a significant booth presence on-ground during the conference.
Novel tool bypasses plasmid-based expression to increase stability and significantly reduce development time for a variety of synthetic biotechnology products
The amalgamation will integrate business operations and provide impetus to the existing portfolio of Alembic
Subscribe To Our Newsletter & Stay Updated
